Tabell
Hovedbudskap |
|
- 3.
Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24: 344 – 54. [PubMed]
- 6.
Spigset O, Molden E. Cytokrom P-450 3A4 - kroppens viktigste arena for legemiddelinteraksjoner. Tidsskr Nor Legeforen 2008; 128: 2832-5. [PubMed]
- 12.
Kongsgaard UE, Kaasa S, Dale O et al. Lindring av smerter hos kreftpasienter. Rapport nr. 9 – 2005. Oslo: Nasjonalt kunnskapssenter for helsetjenesten, 2005.
- 13.
Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. Cochrane Database Syst Rev 2007; CD003868: DOI: 10.1002/14651858.CD003868.pub2. [CrossRef]
- 20.
Lemberg K, Heiskanen T, Kontinen VK et al. Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid? Scand J Pain 2009; 1: S18-S23. [CrossRef]
- 22.
Felleskatalog over farmasøytiske spesialpreparater markedsført i Norge. Oslo: Felleskatalogen A/S, 2009. www.felleskatalogen.no (10.9.2009).